Insider and Institutional Ownership
49.9% of Graybug Vision shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 7.9% of Graybug Vision shares are held by insiders. Comparatively, 1.9% of Orgenesis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Graybug Vision and Orgenesis”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Graybug Vision | $426.96 million | 0.00 | -$35.60 million | ($24.23) | -0.03 |
| Orgenesis | $662,000.00 | 4.61 | -$55.36 million | ($11.51) | -0.05 |
Profitability
This table compares Graybug Vision and Orgenesis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Graybug Vision | N/A | -77.61% | -71.34% |
| Orgenesis | -3,827.81% | N/A | -130.18% |
Risk and Volatility
Graybug Vision has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Orgenesis has a beta of 3.06, meaning that its stock price is 206% more volatile than the S&P 500.
Summary
Graybug Vision beats Orgenesis on 6 of the 11 factors compared between the two stocks.
About Graybug Vision
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.
About Orgenesis
Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.
